Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

ATNM Actinium Pharmaceuticals Inc

8,55

0,77 (9,90%)

03 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Actinium Pharmaceuticals Charts.

Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Actinium Pharmaceuticals Charts.

News Actinium Pharmaceuticals Inc

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Donnerstag 18 April 2024 (2 Wochen vor) • PR Newswire (US)

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual
Montag 1 April 2024 (1 Monat vor) • PR Newswire (US)

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
Dienstag 26 März 2024 (1 Monat vor) • PR Newswire (US)

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand
Montag 11 März 2024 (2 Monate vor) • PR Newswire (US)

Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT
Montag 26 Februar 2024 (2 Monate vor) • PR Newswire (US)

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB
Freitag 23 Februar 2024 (2 Monate vor) • PR Newswire (US)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Freitag 9 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Dienstag 6 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
Freitag 2 Februar 2024 (3 Monate vor) • Edgar (US Regulatory)

Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Dienstag 2 Januar 2024 (4 Monate vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 29 Dezember 2023 (4 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 29 Dezember 2023 (4 Monate vor) • Edgar (US Regulatory)

Weitere Actinium Pharmaceuticals Inc News-Artikel

Euro vs US Dollar

Deutsche Telekom (QX)

Financial Select Sector

Euro vs Sterling

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen